[Immunosuppressive therapy for inflammatory bowel disease: consensus by the Austrian working group on IBD].

Abstract

Azathioprine (AZA) or 6-mercaptopurine (6-MP) are the immunosuppressive drugs of choice in the treatment of inflammatory bowel disorders (IBD). Optimal dosage for AZA is around 2.5 mg/kg body weight and induction of remission by these drugs may take 6 - 7 months. Intramuscularly applied Methotrexate (MTX) is the second choice, while its efficacy starts earlier than that of AZA; studies assessing oral low-dose MTX treatment are lacking. Cyclosporin is the standard treatment in case of steroid-refractory severe ulcerative colitis. This drug may also be used in patients with severe extraintestinal manifestations of IBD. Regarding other immunosuppressive drugs such as mycophenolic acid or 6-thioguanine respective controlled clinical study data are not available. The risk of malignancy using immunosuppressive drugs such as AZA is low and furthermore, especially AZA and 6-MP can be used rather safely during pregnancy.

Statistics

01000200020162017
Citations per Year

201 Citations

Semantic Scholar estimates that this publication has 201 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Reinisch2004ImmunosuppressiveTF, title={[Immunosuppressive therapy for inflammatory bowel disease: consensus by the Austrian working group on IBD].}, author={Walter Reinisch and Clemens Dejaco and Peter Knoflach and Wolfgang Petritsch and Harald Vogelsang and Herbert Tilg}, journal={Zeitschrift für Gastroenterologie}, year={2004}, volume={42 9}, pages={1033-45; discussion 1046-7} }